Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
The present study evaluated cellular and humoral immune parameters in myeloma patients, focusing on the effect of treatment and the risk of opportunistic infections. Peripheral blood lymphocyte subsets and serum levels of nonmyeloma immunoglobulins (Ig) were analysed in 480 blood samples from 77 mye...
Main Authors: | Schütt, P, Brandhorst, D, Stellberg, W, Poser, M, Ebeling, P, Müller, S, Buttkereit, U, Opalka, B, Lindemann, M, Grosse-Wilde, H, Seeber, S, Moritz, T, Nowrousian, MR |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2006
|
Similar Items
-
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
by: Schütt, P, et al.
Published: (2005) -
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
by: Schütt, P, et al.
Published: (2005) -
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
by: Schütt, P, et al.
Published: (2008) -
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
by: Schütt, P, et al.
Published: (2005) -
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
by: Rebmann, V, et al.
Published: (2007)